COLLETTE OMOROGBE: Open Payments
NPI 1922882232 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,451 in 62 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $708 · 2025 $1,451
Food & beverage: $1,340Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $225 |
| ABBVIE INC. | 10 | $205 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $204 |
| E.R. Squibb & Sons, L.L.C. | 4 | $139 |
| Lundbeck LLC | 7 | $131 |
| Neurocrine BioSciences, Inc. | 4 | $112 |
| Vanda Pharmaceuticals Inc. | 4 | $111 |
| Collegium Pharmaceutical, Inc. | 4 | $102 |
| Otsuka America Pharmaceutical, Inc. | 4 | $96 |
| Alkermes, Inc. | 2 | $64 |
Products named: VRAYLAR, CAPLYTA, COBENFY, ABILIFY MAINTENA, INGREZZA, HETLIOZ, Jornay PM, REXULTI.
Industry payments across MD — which companies pay providers there.
